MLL/KMT2A Antikörper (AA 3751-3968)

Produktnummer ABIN969286

Produktdetails anti-MLL/KMT2A Antikörper

Target: MLL/KMT2A (MLL) (Myeloid/lymphoid Or Mixed-Lineage Leukemia (MLL))

Bindungsspezifität: AA 3751-3968

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser MLL/KMT2A Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Aufreinigung: purified

Immunogen: Purified recombinant fragment of MLL (aa3751-3968) expressed in E. coli.

Klon: 10F8D7

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: 4°C, -20°C for long term storage

Referenzen für anti-MLL/KMT2A Antikörper (ABIN969286)

Nigro, Sainati, Leszl, Mirabile, Spinelli, Consarino, Di Cataldo, Magro, Felix, Basso: "Acute differentiated dendritic cell leukemia: a variant form of pediatric acute myeloid leukemia with MLL translocation." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 21, Issue 2, pp. 360-2, (2007) (PubMed).

Partida-Pérez, Domínguez, Sánchez-Corona, Castañeda-Cisneros, García-González, López-Cardona, Rivera: "Constitutional duplication 11q23 de novo involving the MLL gene." in: Genetic counseling (Geneva, Switzerland), Vol. 17, Issue 2, pp. 155-9, (2006) (PubMed).

Kadkol, Bruno, Oh, Schmidt, Lindgren: "MLL-SEPT6 fusion transcript with a novel sequence in an infant with acute myeloid leukemia." in: Cancer genetics and cytogenetics, Vol. 168, Issue 2, pp. 162-7, (2006) (PubMed).

Details zu MLL/KMT2A

Target: MLL/KMT2A (MLL) (Myeloid/lymphoid Or Mixed-Lineage Leukemia (MLL))

Andere Bezeichnung: MLL (MLL Produkte)

Synonyme: ALL-1 antikoerper, CXXC7 antikoerper, HRX antikoerper, HTRX1 antikoerper, MLL antikoerper, MLL/GAS7 antikoerper, MLL1A antikoerper, TET1-MLL antikoerper, TRX1 antikoerper, WDSTS antikoerper, 6430520K01 antikoerper, All1 antikoerper, Cxxc7 antikoerper, Mll antikoerper, Mll1 antikoerper, mKIAA4050 antikoerper, lysine methyltransferase 2A antikoerper, lysine (K)-specific methyltransferase 2A antikoerper, KMT2A antikoerper, Kmt2a antikoerper

Hintergrund:

Description: Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila). Eukaryotic RNA polymerase II mediates the synthesis of mature and functional messenger RNA. This is a multistep process, called the transcription cycle,that includes five stages: preinitiation, promoter, clearance, elongation and termination. Elongation is thought to be a critical stage for the regulation of gene expression. ELL (11-19 lysine-rich leukemia protein, also designated MEN) functions as an RNA polymerase II elongation factor that increases the rateof transcription by suppressing transient pausing by RNA polymerase II. Also, ELL is thought to regulate cellular proliferation. ELL is abundantly expressed in peripheral blood leukocytes, skeletal muscle, placenta and testis, and has lower expression in spleen, thymus, heart, brain, lung, kidney, liver and ovary.The gene encoding human ELL, which maps to chromosome 19p13.1, is one of several genes which undergo translocation with the MLL gene on chromo-some 11q23 in acute myeloid leukemia. MLL (myeloid/lymphoid leukemia,also designated ALL-1 and HRX) is a 430 kDa protein that regulates embryonal and hematopoietic development.

Aliases: MLL

Gen-ID: 4297

HGNC: 4297

Pathways: Warburg Effekt